Investment Thesis — Cencora, Inc.
The market is mispricing Cencora by fixating on its thin margins and high debt, overlooking its essential role in the stable pharmaceutical supply chain and the significant earnings growth implied by its forward P/E. This creates an opportunity to invest in a resilient business with strong cash flow generation at an attractive valuation.
Catalysts
- Consistent earnings beats validating strong forward growth projections.
- Successful deleveraging initiatives improving balance sheet health and reducing perceived risk.
- Potential short squeeze triggered by positive news or sustained price appreciation.
Risk Factors
- Increased regulatory scrutiny or pricing pressure on pharmaceutical distribution margins.
- Failure to achieve projected earnings growth, leading to a re-evaluation of its forward multiple.
- Rising interest rates increasing the cost of its significant debt load and impacting profitability.
Key Debates
COR's 20.5x P/E multiple expands to 23x by Q4 2024
COR's revenue growth accelerates to 9% by Q3 2024
COR reaches analyst price target of $410.50 by H2 2024